Get the Stockscreener App
14.50
1.26%
0.18
After Hours:
14.56
0.06
+0.41%
Ars Pharmaceuticals Inc stock is traded at $14.50, with a volume of 1.13M.
It is up +1.26% in the last 24 hours and up +11.71% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$14.32
Open:
$14.33
24h Volume:
1.13M
Relative Volume:
1.00
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-29.85
EPS:
-0.4858
Net Cash Flow:
$-44.23M
1W Performance:
+2.91%
1M Performance:
+11.71%
6M Performance:
+41.88%
1Y Performance:
+283.60%
1-Day Range:
$14.33
$15.08
1-Week Range:
$13.30
$15.22
52-Week Range:
$3.35
$16.50
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? - Pharmaceutical Technology
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post FY2024 Earnings of ($0.68) Per Share, William Blair Forecasts - MarketBeat
Dr. Thomas Casale discusses the impact of type 1 allergies and new treatments - KOKH FOX25
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray) - Business Wire
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.5% - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
Nasal spray for severe allergies now available in the US By Investing.com - Investing.com Canada
Nasal spray for severe allergies now available in the US - Investing.com
ARS Pharmaceuticals updates manufacturing agreement terms - Investing.com
Nasal spray for severe allergies now available in the US - Investing.com India
ARS Pharmaceuticals Announces U.S. Availability of neffy® - GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - Marketscreener.com
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - StockTitan
Bank of New York Mellon Corp Increases Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00 - MarketBeat
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $140,000.00 in Stock - MarketBeat
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com South Africa
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Canada
Ars pharmaceuticals exec sells $140,000 in company stock - Investing.com
ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com India
Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com India
Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com UK
ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Canada
ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com UK
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com UK
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 3.1% - MarketBeat
Merino closer to Arsenal debut - Tribal Football
Recent Insider Activity Could Benefit ARS Pharmaceuticals Inc (SPRY) - Knox Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down to $13.30 - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Should investors be concerned about ARS Pharmaceuticals Inc (SPRY)? - US Post News
ARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Cantor Fitzgerald - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why - MSN
Investors in cash trouble should check out ARS Pharmaceuticals Inc (SPRY) - SETE News
Ares Management raises over $3.3B of U.S. opportunistic real estate capital (NYSE:ARES) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $22.75 Consensus PT from Brokerages - MarketBeat
Quest Partners LLC Increases Holdings in Resideo Technologies, Inc. (NYSE:REZI) - Defense World
ARS Pharmaceuticals Inc [SPRY] stock for 1,149,775 USD was sold by Tanimoto Sarina - Knox Daily
How To Trade (SPRY) - Stock Traders Daily
ARS Pharmaceuticals Inc: Navigating a Turbulent Year, Up -23.45% from 52-Week Low - The InvestChronicle
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow - Simply Wall St
There is no way ARS Pharmaceuticals Inc (SPRY) can keep these numbers up - SETE News
ARS Pharmaceuticals (SPRY): A Bull Case Theory - Yahoo Finance
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan
ARS Pharmaceuticals Inc (SPRY) did well last session? - US Post News
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):